Viridian Therapeutics Inc (NASDAQ:VRDN) shares, rose in value on Thursday, December 12, with the stock price down by -5.19% to the previous day’s close as strong demand from buyers drove the stock to $17.99.
Actively observing the price movement in the last trading, the stock closed the session at $18.98, falling within a range of $17.96 and $19.0. The value of beta (5-year monthly) was 1.114. Referring to stock’s 52-week performance, its high was $27.20, and the low was $11.40. On the whole, VRDN has fluctuated by -19.79% over the past month.
With the market capitalization of Viridian Therapeutics Inc currently standing at about $1.43 billion, investors are eagerly awaiting this quarter’s results, scheduled for in January.
Wall Street analysts also predicted that the company’s y-o-y revenues would reach 48.77k.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that VRDN’s technical picture suggests that short-term indicators denote the stock is a Hold on average. However, medium-term indicators have put the stock in the category of 50% Buy while long-term indicators on average have been pointing out that it is a 50% Buy.
The stock’s technical analysis shows that the price of VRDN currently trading nearly -11.07% and -18.95% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 29.52, while the 7-day volatility ratio is showing 3.75% which for the 30-day chart, stands at 5.00%. Furthermore, Viridian Therapeutics Inc (VRDN)’s beta value is 1.11, and its average true range (ATR) is 1.02.
A comparison of Viridian Therapeutics Inc (VRDN) with its peers suggests the former has fared considerably weaker in the market. VRDN showed an intraday change of -5.19% in last session, and over the past year, it grew by 4.71%%.
Data on historical trading for Viridian Therapeutics Inc (NASDAQ:VRDN) indicates that the trading volumes over the past 10 days have averaged 0.9 and over the past 3 months, they’ve averaged 1.19 million. According to company’s latest data on outstanding shares, there are 79.18 million shares outstanding.
Nearly 11.04% of Viridian Therapeutics Inc’s shares belong to company insiders and institutional investors own 98.98% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 8.75 million shares as on 2024-11-29, resulting in a short ratio of 7.68. According to the data, the short interest in Viridian Therapeutics Inc (VRDN) stood at 1255.00 of shares outstanding as of 2024-11-29; the number of short shares registered in 2024-10-31 reached 10.02 million. The stock has fallen by -17.40% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the VRDN stock heading into the next quarter.
